Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2003 Apr;14(4):520-35.

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

Author information

Clinic I of Internal Medicine, University Hospital of Cologne, Germany.

Erratum in

  • Ann Oncol. 2003 Jun;14(6):967.


The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin's lymphoma (NHL). To date, more than 300 000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin's disease and other B-cell malignancies. Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different studies. Rituximab is now also approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center